- /
- Supported exchanges
- / F
- / 3NK.F
ALPHAMAB ONCOLO.DL-000002 (3NK F) stock market data APIs
ALPHAMAB ONCOLO.DL-000002 Financial Data Overview
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is in Phase III clinical trials for treatment of HER2-positive breast cancer and HER2- positive gastric cancer or gastroesophageal junction cancer; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in Phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; JSKN016, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced malignant solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ALPHAMAB ONCOLO.DL-000002 data using free add-ons & libraries
Get ALPHAMAB ONCOLO.DL-000002 Fundamental Data
ALPHAMAB ONCOLO.DL-000002 Fundamental data includes:
- Net Revenue: 640 M
- EBITDA: 165 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.